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Abstract
Background: Osteosarcoma is a typical bone cancer that primarily affects adolescents. The therapeutic activity of
drugs is limited by their severe drug-related toxicities, therefore, a therapeutic approach which is less toxic and
highly effective in tumor is of utmost importance.
Method: In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles
(PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells. The
drug-loaded nanoparticle was characterized for physical and biological characterizations.
Results: The formulated PD/IFS showed a high drug loading capacity and displayed a pH-sensitive release pattern,
with a sustained release profile of the IFS. PD/IFS nanoparticles exhibited remarkable in vitro anticancer activity
comparable to that of free IFS solution in a concentration dependent manner in MG63 and Saos-2 cancer cells.
PLGA-dextran by itself did not affect cell viability of cancer cells indicating its excellent biocompatibility. The
formulation exhibited significantly higher PARP and caspase-3/7 expression in both the cancer cells.
Conclusion: Our study successfully demonstrated that nanoparticulate encapsulation of antitumor agent will
increase the therapeutic efficacy and exhibit a greater induction of apoptosis and cell death.
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Background
Osteosarcoma (OS) is one of the typical bone cancers
that occur in distal femur and proximal tibia [1]. OS be-
ing mesenchymal in nature are very aggressive and more
than 20 % of cases are diagnosed at metastatic stage.
Specifically, OS is commonly seen in children and ado-
lescents [2]. Parallel to other solid tumors, OS tumors
also contains a highly heterogeneous population of can-
cer cells in terms of growth rate, karyotype, antigenicity
and chemosensitivity. Although 5-year survival rate in-
creased to 65 %, yet it is way behind the overall cancer
survival rate [3, 4]. Furthermore, survival rate of 5-year
metastatic disease is still at a meager 20 %. At present,
the therapies for OS treatment include surgical resection
followed by chemotherapy regimens of various drugs in-
cluding doxorubicin, cisplatin, and ifosfimide [5]. How-
ever, therapeutic activity of these drugs is limited by
their severe drug-related toxicities such as cardiotoxicity
and nephrotoxicity. Therefore, a therapeutic approach
which is less toxic and highly effective in tumor is of ut-
most importance [6]. In this regard, present research is
mainly focused on developing unique and novel thera-
peutic carriers to deliver the chemotherapeutic drugs to
the cancer cells.
Ifosfamide (IFS) is a DNA-alkylating agent and a struc-
tural analog of cyclophosphamide. It acts as a prodrug,
its metabolism occurring mainly through CYP 3A4 and
CYP 2B6 enzymes, which are present predominantly in
the hepatocytes [7, 8]. IFS crosslinks DNA strands and
inhibits DNA replication and ultimately leads to apop-
tosis due to activation of caspases in the cells. IFS is in-
dicated as a mainline treatment for OS and delivered as
an intravenous infusion [9]. A variety of nanoparticle-
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based delivery systems have been developed for the de-
livery of anticancer drugs. Self-assembled polymeric
nanoparticles, have received increased attention for their
potential application in biotechnology and medicine, es-
pecially as a drug delivery carrier in cancer therapeutics
[10]. These amphiphilic nanoparticles usually have a
hydrophobic core shielded by a hydrophilic shell when
present in the aqueous environment. The hydrophobic
core involves in the drug incorporation and the outer
hydrophilic shell prevents the delivery system against re-
ticuloendothelial system (RES) [11]. The polymeric self-
assembled nanoparticles offer some unique advantages
including core-shell morphology, high loading capacity,
site-specific drug delivery, and avoids unwanted side ef-
fects of administered drug. Moreover, micelles remain
stable in blood circulation for prolonged period of time
and could avail enhanced permeability and retention ef-
fect (EPR) based passive targeting [12, 13].
Dextran, a polysaccharide is characterized as a col-
loidal and hydrophilic substance [14]. Dextran is exten-
sively employed as a delivery carrier owing to its
excellent biocompatible and immunoneutral properties.
Moreover, hydroxyl group present in the glucose unit
allow for easy chemical conjugations [15]. Biodegradable
polymer, poly(lactic-co-glycolic acid) (PLGA) was se-
lected due to its excellent systemic characteristics and
biodegradability. Several studies have reported that
nanosized PLGA NP would be in the ideal range of EPR
effect as well as to avoid reticuloendothelial system
(RES) mediated clearance. However, delivery characteris-
tics of PLGA could be further improved by conjugating
with hydrophilic dextran sulphate (DS) [16]. Recently,
Jeong et al. reported that PLGA-dextran block copoly-
mer forms self-assembling nanoparticles and could be
used as a carrier to deliver multiple anticancer agents
[17]. Consistently, we have synthesized a PLGA-dextran
block copolymer via EDC/NHS chemistry and encapsu-
lated IFS. We expected that incorporation of IFS in
PLGA-dextran based polymeric nanoparticles will effect-
ively increase the chemotherapeutic efficacy in cancers
while at the same time reduce the overall side effects.
Thus far, the main aim of this study was to prepare
ifosfamide-loaded PLGA-dextran polymeric nanoparti-
cles for the treatment of osteosarcoma (OS). We hypoth-
esized that IFS incorporation in a nanocarrier would
increase its therapeutic effect due to the controlled re-
lease and defined properties. The dynamic light scatter-
ing analysis and morphology analysis were carried out to
optimize the formulations. The biocompatible nature of
blank nanoparticles (NP) and cytotoxic effect of IFS-
loaded NP was evaluated in MG63 and Saos-2 osteosar-
coma cells via MTT assay. The apoptotic effect of free
drug and IFS-loaded NP was studied means of PARP
and caspase-3, which are typical apoptotic markers.
Materials and methods
Materials
Ifosfamide (≥98 %) was purchased from Sigma Aldrich
(St. Louis, MO, USA).Poly(d,l-lactic-co-glycolic acid)
(PLGA) (Mw: 10,000; lactic acid : glycolic acid = 50:50)
was procured from Wako Pure Chemical (Tokyo, Japan).
Dextran from Leuconostocspp was also obtained from
Sigma-Aldrich (China). All other chemicals were reagent
grade and used without further purifications.
Synthesis of PLGA-Dextran block copolymer
Approximately 3 g of PLGA-COOH was dissolved in an-
hydrous methylene chloride and to this organic solution,
70 mg of NHS (N-hydroxysuccinimide) and 140 mg of
EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide)
was added. The organic mixture was stirred continu-
ously for 12 h at room temperature. The 12 h time
period is sufficient for the complete activation of carbox-
ylic acid group in PLGA. The formed PLGA-NHS was
precipitated by the addition of ice cold ether, washed
with organic solvent mixture, and dried.
Aminated dextran was prepared as reported previ-
ously. Briefly, dextran and cyanoborohydride was mixed
in a DMSO medium and to this mixture hexamethylene
diamine was added and allowed the reaction for 24 h.
The amine group terminated dextran was collected, dia-
lyzed, and lyophilized. To prepare the block copolymer,
100 mg of PLGA-NHS and 125 mg of dextran was dis-
solved in DMSO and inert atmosphere was maintained
throughout the reaction time. The formed PLGA-dextran
was dialyzed using dialysis membrane (molecular weight
cutoff, 10,000 g/mol) for 3 days. The resulting products
was lyophilized and dried under vacuum conditions.
Preparation of Ifosfamide-loaded polymeric nanoparticles
IFS-loaded polymeric nanoparticles (NP) were prepared
by precipitation method. In brief, 25 mg of PLGA-
dextran (PLD) and 5 mg of IFS were dissolved in 5 ml of
DMSO and to this mixture 20 ml of ultra-pure water
were added. The mixture was magnetic stirred for 2 h
and followed by dialysis against distilled water. The dia-
lysis process was continued for 3–4 h and the resulting
drug-loaded polymeric NP was collected and lyophilized.
Drug loading
The loading efficiency and loading capacity was determined
as follows. In brief, 10 mg of lyophilized NP was dissolved
in 5 ml of DMSO and sonicated for 15 min. The organic
solution was centrifuged and the supernatant was used to
calculate the amount of drug loaded. The drug loading was
quantified using HPLC method. The HPLC system
(Shimadzu, Kyoto, Japan) consisted of LC-10AT pump, a
SPD-10A UV/Vis detector and a DGU-14A degasser
model. The flow rate was maintained at 1 ml/min. The
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wavelength of detection was 254 nm. 50 mM of KH 2 PO 4
(pH 5.0) was used as a mobile phase.
Particle size and size distribution analysis
The average particle size and size distribution analysis
was performed using a Zetasizer Nano-S90 (Malvern In-
struments, Malvern, UK) and a 633 nm He-Ne laser
beam at a fixed scattering angle of 90°. A dilute solution
of NP was used to analyse the particle size. The experi-
ments were performed in triplicates.
Transmission electron microscopy
The morphology of the PD/IFS was examined on a
transmission electron microscope (JEOL JEM-200CX).
Before the examinations, NP dispersion was diluted
many times with ultra-pure water. The aqueous solution
was dropped on the carbon coated copper grid and
counter stained with 2 % phosphotungistic acid. The
samples were dried using an infrared lamp and viewed
under TEM.
Drug release study
The IFS release from the PD/IFS NP system was deter-
mined using a dialysis method. Briefly, 30 mg of PD/IFS
lyophilized powder was dissolved in 1 ml of water and
sealed in a dialysis tube. The dialysis tube was in turn
placed in a 50 ml of Falcon tube containing 25 ml of re-
lease media. Selective release media including phosphate
buffered saline (PBS, pH 7.4) and acetate buffered saline
(ABS, pH 5.5) was used. The main reason behind the se-
lection of different pH was to mimic the conditions of
tumor microenvironment. The sampling was done at spe-
cific time points such as 1,2,4.6,8,10,12,24,48,72,96,120 h.
At each sampling point, 1 ml of release sample was with-
drawn and replaced with equal volume of fresh media.
The released IFS content in the released medium was de-
termined by HPLC as previously described.
Cell culture
MG63 and Saos-2 osteosarcoma cancer cells were grown in
DMEM supplemented with 10 % FBS, 100 units/mL peni-
cillin and 100 μg/mL of streptomycin. Cells were main-
tained at 37 °C with 5 % CO2 in a humidified incubator.
Cell viability assay
Cell viability was assessed using 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) calorimetric
assay. MG63 and Saos-2 osteosarcoma cancer cells were
seeded in a 96-well plate (4000 cells/well) and allowed to
grow for 48–72 h. Next day, media was removed and re-
placed with fresh media containing blank PLGA-dextran,
free IFS, and PD/IFS NP in a concentration-dependent
manner. The formulations were incubated for 24 h and
cell viability was estimated using MTT solution. MTT
reagent 20 μL in PBS was added into each well and the
plate was incubated for 4 h at 37 °C. The culture medium
in the wells was removed and 200 μL of dimethylsulfoxide
(DMSO) was added into the wells. The optical density of
the solution was measured at 570 nm with a micro-
plate reader. The mean value and standard deviation
for each treatment were determined and then con-
verted values relative to the control. IC50 were calcu-
lated using GraphPad Prism software.
Morphological cell imaging
Cover slips were rinsed in 70 % ethanol for 10 min and
washed with PBS. The cells were seeded into the cover
slips and allowed to attach for 12 h. The formulations as
mentioned above was added to each well and further in-
cubated for 24 h. Then samples were washed with PBS,
fixed with formalin (Sigma), and viewed under Nikon
Eclipse 60i microscope system.
Caspase-3 activity
The activity of caspase-3 was measured by colorimetric
assay kits (Sigma-Aldrich) as per the manufacturer’s pro-
tocols. MG63 and Saos-2 osteosarcoma cancer cells were
seeded in a 6-well plate (1 × 106 cells/well) and allowed to
attach for 24 h. Next day, media was removed and re-
placed with fresh media containing blank PLGA-dextran,
free IFS, and PD/IFS NP in a concentration-dependent
manner. The cells were incubated with respective formu-
lations for 24 h. Cell pellets were collected and treated
with lysis buffer and incubated for 10 min in ice bath. The
lysate was collected, centrifuged and supernatant was col-
lected and evaluated for caspase-3 activity.
Apoptosis analysis
FACS analysis is considered to be a specific and objective
method for quantitative determination of apoptosis. MG-
63 and Saos-2 cells were seeded at a density of 5 × 105
cells in a 6-well plate and incubated for 24 h. When the
cells reached 80 % confluence, cells were treated with free
IFS, and PD/IFS NP formulations (1 μg/ml) and further
incubated for 24 h. Following day, cells were harvested,
washed, and incubated with a mixture of 0.25 mg/mL
Annexin-V FITC and 10 mg/mL PI. The mixture was kept
for 15 min at 37 °C. Excess PI and AV-FITC fluorescence
were then washed off and cells were measured by flow cy-
tometry (FACS Calibur, BD Biosciences). A minimum of
10,000 events was counted per sample by flow cytometry.
Statistical analysis
Results in the present study are presented as means ±
standard deviations. Statistical significance was evaluated
by analysis of variance (ANOVA), followed by Tukey’s
post-hoc test. *P-values of p < 0.05 was considered to be
statistically significant.
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Results
Characterization of PD/IFS nanoparticles
PLGA-dextran formed self-assembled polymeric micelles
in the aqueous medium. Generally, PLGA is hydropho-
bic, so it should form the inner core of the polymeric
micelle while the dextran domain should form the outer
shell due to its hydrophilic nature [18]. Polymeric mi-
celles incorporated drugs by the hydrophobic interaction
between the drug and the hydrophobic domain of the
block copolymer. It has been frequently reported that
polymeric micelles enhances accumulation in tumor
cells and prolongs blood circulation times [19].
Particle size analysis
The particle size and size distribution of PD/IFS NP was
investigated by means of dynamic light scattering (DLS)
technique. The particle size of PD/IFS was observed to
be 124 ± 3.45 nm with an excellent dispersity index of
0.124 (PDI) (Fig. 1a). Blank polymeric micelles posted an
average size of 75 ± 2.39 nm. The increase in particle size
upon drug incorporation might due to the bulkier core
of micellar system. Furthermore, it has been frequently
reported that small particle size <200 nm could accumu-
late preferentially in the tumor tissues via enhanced per-
meability and retention (EPR) effect. Other than this,
small particle size could effectively evade the RES based
clearance system in the blood circulation [19].
Morphological analysis
The particle size of PD/IFS NP was further confirmed by
TEM imaging. As seen from Fig. 1b, particle sizes were
in the range of 60–80 nm and uniformly distributed in
the carbon coated copper grid. The particles were clearly
spherical and present as a dense black object the TEM
grid. No apparent sign of aggregation was seen among
the particles. It has to be noted that particle size ob-
served form TEM was smaller than observed from DLS
analysis. The difference in particle size might be attrib-
uted to the dried state (from TEM) and hydrated state
(from DLS) of particles.
Drug loading and In vitro drug release
IFS was effectively entrapped in the NPs with a loading
and encapsulation efficiency of 20.15 ± 3.5 % and 89 ±
1.95 %, respectively. The release profile of IFS from PD/
IFS NP was performed in phosphate buffered saline (PBS)
and acetate buffered Saline (ABS) at 37 °C. Results showed
that IFS released in a sustained manner throughout the
study period up to 96 h (Fig. 2). As expected, PD/IFS
showed a pH-dependent release profile with accelerated
release in the acidic pH than comparing to that of physio-
logical pH conditions. It has to be noted that accelerated
release of drug from the NP might be attributed to the fast
diffusion of drug and partially due to the higher degrad-
ation of delivery vehicle in the acidic conditions. Broadly,
release profile of IFS in pH 7.4 and pH 5.0 could be di-
vided into two parts; first, faster release of IFS was ob-
served until 24 h and second, a relatively more sustained
release phenomenon was observed from 24 to 96 h study
period. For example, nearly ~30 % of IFS released in first
24 h while only ~55 % of drug released by the end of 96 h
in PBS media. Similar trend was observed in ABS media,
where nearly ~40 % of drug released in24h and completed
the release (100 %) by the end of 96 h. The sustained re-
lease of drug in pH 7.4 condition and accelerated release
in pH 5.0 conditions would be advantageous in cancer
drug delivery.
Cytotoxicity assay and cellular morphology
The cancer cells were treated with blank NP with differ-
ent concentrations ranging from 0.1 to 100 μg/mL
(Fig. 3a, b). The results clearly showed that synthesized
polymers were highly biocompatible and showed a cell
viability of more than 90 % throughout all the concentra-
tions tested. Fluorescent images of MG63 cells showed
that cells maintained their morphology when incubated
with blank NP (Fig. 3c). The polymeric carrier itself did
not contribute to cytotoxicity is very advantageous.
Cytotoxic potential of free IFS and PD/IFS was evalu-
ated in both the osteosarcoma cancer cell lines. The cells
were cultured in the presence of free IFS and PD/IFS NP
at increasing concentrations of drugs. As shown in
Fig. 1 a Particle size distribution of ifosfamide-loaded PLGA-dextran (PD/IFS) nanoparticles b TEM image of PD/IFS
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Fig. 4a, b, both free IFS and PD/IFS were able to effect-
ively inhibit cell growth and showed a concentration
dependent-cytotoxic effect.
Furthermore, morphology of cells treated with free IFS
and PD/IFS NP was evaluated by optical microscope. In
both the case, untreated cells presented a well-defined
morphology and adhered to the cover slip in the 6-well
plate (Fig. 4c, d). In case of PD/IFS treated group,
marked presence of dead cells were observed. The cells
were either fusiform or rounded and in the process of
dying indicating the cytotoxic effect of the optimized
formulations.
Fig. 2 The release profile of IFS from PLGA-dextran nanoparticulate system. The release study was performed in phosphate buffered saline and
acetate buffered saline. The study was carried out for 96 h.**p < 0.01 is the statistical difference between pH 7.4 and pH 5.5 release medium
Fig. 3 Cytotoxicity assay for blank nanoparticles in a MG63 b Saos-2 osteosarcoma cancer cells. c Confocal laser scanning microscopic images
of PD/IFS
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Cellular apoptosis analysis
The ability free IFS and PD/IFS NP to induce apoptosis
on representative MG63 and Saos-2 cancer cell was eval-
uated by means of Annexin-V/PI-mediated apoptosis
analysis. It can be clearly seen (Fig. 5a, b) that PD/IFS
induced a greater apoptosis rate in both the cancer cells.
Caspase-3 activity was analysed in the cancer cells to
further prove the apoptosis behaviour of respective for-
mulations (Fig. 6a, b). Consistent with apoptosis analysis,
PD/IFS showed a significantly (p < 0.01) higher expres-
sion of caspase 3 in MG63 cancer cells in a concentra-
tion dependent manner. Similar trends were observed in
Saos-2 cancer cells however, caspase-3 level was rela-
tively than expressed in MG63 cells.
Discussion
Osteosarcoma (OS) is one of the typical bone cancers
that occur in distal femur and proximal tibia. Although
technological advancement increased the 5-year survival
rate to 65 %, yet it is way behind the overall cancer sur-
vival rate. Furthermore, the metastatic or recurring
disease 5-year survival rate is still at a meager 20 %. At
present, the therapies for OS treatment include surgical
resection followed by chemotherapy regimens of various
drugs including doxorubicin, cisplatin, and ifosfamide.
Specifically, IFS, a DNA-alkylating agent is indicated as a
mainline treatment for OS. IFS crosslinks DNA strands
and inhibits DNA replication and ultimately leads to
apoptosis due to activation of caspases in the cells. In
order to increase its therapeutic efficacy, it has to be
loaded in nanoparticle-based delivery systems. A self-
assembled polymeric nanoparticle which has a hydro-
phobic core, involves in the drug incorporation and the
outer hydrophilic shell prevents the delivery system
against reticuloendothelial system (RES). In this study,
PLGA-dextran copolymer was synthesized and used to
encapsulate IFS. Biodegradable polymer, poly(lactic-co-
glycolic acid) (PLGA) was selected due to its excellent
systemic characteristics and biodegradability. Dextran
was selected due to its hydrophilic nature and biocompati-
bility. Dextran has an advantage, in that it has a confluent
functional (hydroxyl) group in its chain, and the hydroxyl
Fig. 4 Cytotoxicity of free IFS and PD/IFS (with equivalent IFS concentration) on (a) MG63 (b) Saos-2 osteosarcoma cancer cells. The cytotoxicity
assay was performed by MTT technique. The cells were incubated for 24 h and the experiment was repeated four times in triplicate. Optical
images of (c) MG63 (d) Saos-2 cells after incubation with free IFS and PD/IFS for 24 h. **p < 0.01 is the statistical difference between IFS and PD/
IFS in both cancer cells
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group can be used for chemical modification with target-
ing moieties. To conjugate PLGA copolymer, −COOH
group of PLGA was activated by means of NHS to form
PLGA-NHS. This PLGA-NHS was then mixed with ami-
nated dextran to form block copolymer (Fig. 7). We ex-
pected that incorporation of IFS in PLGA-dextran based
polymeric nanoparticles will effectively increase the che-
motherapeutic efficacy in cancers while at the same time
reduce the overall side effects.
One of the most important criteria for successful
cancer targeting is the development of a biocompat-
ible and safe nanoparticulate system. The biocom-
patibility of PLGA-dextran blank NP was studied in
MG63 and Saos-2 osteosarcoma cancer cells. The re-
sults clearly showed that synthesized polymers were
highly biocompatible and showed a cell viability of
more than 90 % throughout all the concentrations
tested.
Cytotoxic potential of free IFS and PD/IFS was evalu-
ated in both the osteosarcoma cancer cell lines. Through-
out all the concentrations, PD/IFS showed significant
anticancer effect than comparing to free IFS. IC50 values
of free IFS and PD/IFS NP were determined to quantify
the cytotoxic effect. IC50 value of free IFS and PD/IFS NP
were 5.24 μg/ml and 0.932 μg/ml, respectively in MG63
cancer cells, whereas, it was 5.46 μg/ml and 1.046 μg/ml,
respectively in Saos-2 cancer cells. It should be mentioned
that PLGA-dextran alone did not affect cell viability.
Therefore, the therapeutic efficacy is only due to the drug
loaded within the nanoparticles. The nanoparticle
adsorbed onto the cell membrane which resulted in an in-
crease in the intracellular drug concentration, offering a
Fig. 5 Apoptosis analysis was detected by Annexin-V/PI staining. Apoptosis of a MG63 b Saos-2 cancer cells. The respective cell percentages in
early and late apoptosis for different time period are presented in the bar graph. **p < 0.01 is the statistical difference in apoptosis between IFS
and PD/IFS in both cancer cells
Fig. 6 Caspase-3activity was measured as a second parameter of apoptotic cell death in a MG63 b Saos-2 cancer cells. Significant increase in
apoptosis was observed when they were treated with IFS loaded nanoparticle. *p < 0.05 and **p < 0.01 is the statistical difference between IFS
and PD/IFS in both cancer cells
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gradient that would favour drug influx into the cells [20].
Moreover, efficient uptake of NP could be a potential con-
tributing factor in the enhanced cytotoxic effect of delivery
systems [21].
Consistent with cytotoxicity assay, PD/IFS showed a
significantly (p < 0.01) higher apoptosis of cancer cells in
MG63 cancer cells. Similar trends were observed in
Saos-2 cancer cells however, apoptosis rate was relatively
than MG63 cells. The difference in apoptosis rate be-
tween two cell lines could be due to the biological origin
and its growth rate. Consistent with cell apoptosis, PD/
IFS showed a significantly (p < 0.01) higher expression of
caspase 3/7 in MG63 cancer cells in a concentration
dependent manner. Similar trends were observed in
Saos-2 cancer cells however, caspase-3 level was rela-
tively than expressed in MG63 cells. Therefore it is clear
that nanoparticulate formulation of IFS remarkably in-
creased the therapeutic performance of anticancer drug.
In the clinical setting, anticancer drugs often lead to
systemic toxicity which restricts the overall dose. A lim-
ited dose however will limit the therapeutic index of
given anticancer drugs. This essentially promotes the
phenomenon of multi drug resistance (MDR) in cancer
cells which will further complicate the drug treatment.
In this regard, EUROMOS trail shows that free drug
(IFS) does not improve the post-operative chemotherapy
and patients responded poorly. In addition, IFS in-
creased the number of side effects in various patients.
Therefore, we believe the incorporation of IFS in a nano-
particulate system could potentially improve its thera-
peutic efficacy while at the same time is expected to
reduce its side effects. Our study successfully demon-
strated that nanoparticulate encapsulation of antitumor
agent will increase the therapeutic efficacy and exhibit a
greater induction of apoptosis and cell death. It seems
that the nanoparticle delivery system caused increased
uptake of IFS and distribution in the nucleus resulting in
the enhanced cell death [22]. Our study is consistent
with previously published report that nanoparticle-drug
conjugates induce stronger activation of apoptosis sig-
nalling pathways comparing to that of free drug. A thor-
ough study on experimental animal models and different
cell panel would bring more value to the osteosarcoma
treatment.
Conclusion
Ifosfamide-loaded PLGA-dextran polymeric nanoparticles
(PD/IFS) were successfully developed and studied its anti-
cancer efficacy against multiple osteosarcoma cancer cells.
The drug-loaded nanoparticle was characterized in terms
Fig. 7 Schematic illustration of conjugation of PLGA polymer with the dextran block. The ifosfamide and block copolymer self-assembled to form
the polymeric nanoparticles
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of size distribution, morphology, zeta potential, drug load-
ing, release profile, cytotoxicity assay, and apoptosis in-
duction. The formulated PD/IFS showed a high drug
loading capacity and displayed a pH-sensitive release pat-
tern, with a sustained release profile of the IFS. This prop-
erty is important for all the biomedical applications
including cancer chemotherapy. PD/IFS nanoparticles ex-
hibited remarkable in vitro anticancer activity comparable
to that of free IFS solution in a concentration dependent
manner in MG63 and Saos-2 cancer cells. PLGA-dextran
by itself did not affect cell viability of cancer cells indicat-
ing its excellent biocompatibility. The formulation exhib-
ited significantly higher PARP and caspase-3 expression in
both the cancer cells. Our study successfully demonstrated
that nanoparticulate encapsulation of antitumor agent will
increase the therapeutic efficacy and exhibit a greater in-
duction of apoptosis and cell death. Thus, IFS-loaded
PLGA-dextran based formulations could be a potential
candidate for the treatment of osteosarcoma.
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